Hikma Pharmaceuticals Regulatory News (HIK)

26 Jan 2007 10:49

Hikma Pharmaceuticals Plc26 January 2007 Hikma completes its acquisition of Ribosepharm LONDON, 26 January 2007 - Following the announcement made by HikmaPharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the multinationalpharmaceuticals group, on 22 January 2007 regarding the acquisition ofRibosepharm GmbH, Hikma today announces that the transaction has been completed. Samih Darwazah, Chairman & CEO of Hikma, commented: "The acquisition ofRibosepharm provides us with an excellent platform from which to enter the largeand fast-growing oncology market, which is forecast to become the second largestwithin the pharmaceutical industry by 2010. Ribosepharm has a strong position inGermany, one of the largest European oncology markets, and significantdistribution capabilities. We will be able to draw on its experience in thefield of oncology and use its expertise to expand into other oncology markets inEurope, as well as into the United States and the MENA region. We look forwardto working with Dr. Kudielka, Ribosepharm's Managing Director, and hisexperienced team." - ENDS -Enquiries: Hikma Pharmaceuticals PLC Susan Ringdal, Investor Relations Director +44 20 7399 2760 Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. About Ribosepharm Ribosepharm is a well-established and successful oncology company, specialisingin the marketing and distribution of branded generic injectable oncologyproducts both to private practices and hospitals in Germany. This information is provided by RNS The company news service from the London Stock Exchange